Frontlight ResearchEarly access
Taking people in United StatesPhase 2
Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms
Key facts
- Who runs it
- University of California, Irvine
- Where
- Orange, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 15 people, planned
- Started
- 18 Jun 2026
- Expected to end
- Jul 2029
- Type of study
- Interventional
- Treatments tested
- Metformin
- Record updated
- 13 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (6)Hide the full registry criteria
Who can take part
- Patients with clinical diagnosis of pseudomyxoma peritonei (PMP) secondary to presumed appendiceal mucinous neoplasms (AMNs) with recurrent/refractory disease s/p cytoreductive surgery(CRS)/hyperthermic intraperitoneal chemotherapy (HIPEC), unresectable disease, or without planned CRS/HIPEC
- Age ≥18 years
- ECOG performance status ≤2
Who cannot take part
- Patients currently taking metformin for another medical indication
- Patients with a prior adverse event to administration of metformin
- Patients with a clinical diagnosis of PMP secondary to presumed AMNs with resectable disease who are planned to undergo CRS/HIPEC
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Appendiceal mucinous neoplasm or pseudomyxoma peritonei
This trial is currently available in United States.
- Chao Family Comprehensive Cancer Center, University of California, IrvineOrange, United StatesContact: Oliver Eng, MDTaking people
About the trial
What the trial wants to find out
This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritonei (PMP) secondary to appendiceal mucinous neoplasms (AMNs).
The group in the trial
- Metformin TreatmentTreatment being tested
850mg PO daily
Treatment: Metformin
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
Download the PDF
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Use of Metformin in Patients With Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms
- Criteria questions
- Built from NCT07693452, who can take part
- Record updated
- 13 July 2026